# Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101

> **NCT02008539** · PHASE1,PHASE2 · TERMINATED · sponsor: **Apceth GmbH & Co. KG** · enrollment: 13 (actual)

## Conditions studied

- Advanced Gastrointestinal Cancer

## Interventions

- **DRUG:** MSC_apceth_101

## Key facts

- **NCT ID:** NCT02008539
- **Lead sponsor:** Apceth GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2016-09-07
- **Final completion:** 2016-09-07
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Enrollment terminated after 13 patients (14 planned); further patients did not meet eligibility criteria to receive autologous IMP
- **Last updated:** 2017-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02008539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02008539, "Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT02008539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*